Current standards and novel developments in the treatment of neuroendocrine tumors of the gastroenteropancreatic system

被引：2

作者：

Auernhammer, Christoph Josef ^{[1
,5
]}

Spitzweg, Christine ^{[1
,5
]}

Boeck, Stefan ^{[2
,5
]}

Knoesel, Thomas ^{[3
,5
]}

Bartenstein, Peter ^{[4
,5
]}

机构：

[1] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Med Klin & Poliklin 4, Munich, Germany

[2] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Med Klin & Poliklin 3, Munich, Germany

[3] Ludwig Maximilians Univ Munchen, Inst Pathol, Munich, Germany

[4] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Klin & Poliklin Nuklearmed, Munich, Germany

[5] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Interdisziplinares Zentrum Neuroendokrine Tumoren, Campus Grosshadern, Munich, Germany

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2019年 / 144卷 / 20期

关键词：

neuroendocrine tumors; biotherapy; peptid receptor radionuclide therapy (PRRT); chemotherapy; molecular targeted therapy;

D O I：

10.1055/a-0801-3686

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Current guidelines have been published for the diagnosis and therapy of neuroendocrine neoplasms of the gastroenteropancreatic (GEP) system 1 . Systemic therapy of inoperable advanced neuroendocrine tumors includes biotherapy with somatostatin analogas, peptid receptor radionuclide therapy (PRRT) with 177Lutetium-DOTA-TATE, chemotherapy with steptozotocin/5-fluorouracil or capecitabine/temozolomide and molecular targeted therapy with everolimus or sunitinib 1 2 . For symptom control in patients with carcinoid syndrome biotherapy with somatostatin analogs, PRRT, loco-regional and local-ablative interventional procedures of liver metastases as well as the peripheral serotonin synthesis inhibitor telotristat Ethyl 1 2 3 4 are highly effective. Novel aspects and developments in the diagnosis and treatment of neuroendocrine tumors will be discussed in this review.

引用

页码：1390 / 1395

页数：6

共 50 条

[1] Current developments in the treatment of neuroendocrine tumors
Kiesewetter-Wiederkehr, Barbara
Melhorn, Philipp
Scheuba, Christian
Raderer, Markus
[J]. RADIOLOGIE, 2024, 64 (07): : 568 - 574
[2] Novel Therapeutic Agents for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Pavel, M. E.
Wiedenmann, B.
[J]. HORMONE AND METABOLIC RESEARCH, 2011, 43 (12) : 844 - 853
[3] Treatment of gastroenteropancreatic neuroendocrine tumors
U. Plöckinger
B. Wiedenmann
[J]. Virchows Archiv, 2007, 451 : 71 - 80
[4] Treatment of gastroenteropancreatic neuroendocrine tumors
Ploeckinger, U.
Wiedenmann, B.
[J]. VIRCHOWS ARCHIV, 2007, 451 (Suppl 1) : S71 - S80
[5] Novel Agents in Gastroenteropancreatic Neuroendocrine Tumors
Stevenson, Ryan
Libutti, Steven K.
Saif, Muhammad Wasif
[J]. JOURNAL OF THE PANCREAS, 2013, 14 (02): : 152 - 154
[6] Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors
Saif, Muhammad Wasif
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (03) : 443 - 456
[7] Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Phan, Alexandria T.
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (12) : 3 - 5
[8] Treatment Approaches in Gastroenteropancreatic Neuroendocrine Tumors
Phan, Alexandria T.
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (05) : 7 - 12
[9] Advances in the treatment of gastroenteropancreatic neuroendocrine tumors
Kunz, Pamela L.
Fisher, George A.
[J]. CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2010, 3 : 79 - 86
[10] Medical treatment of gastroenteropancreatic neuroendocrine tumors
Ferru, A.
Chabrun, V.
Tourani, J. -M.
[J]. MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2009, 33 (11): : 718 - 723

← 1 2 3 4 5 →